A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Tyrosine kinase inhibitors (TKIs) targeting EGFR-mutant lung cancers promote a range of tumor regression responses to yield variable residual disease, a likely incubator for acquired resistance. Herein, rapid transcriptional responses induced by TKIs early in treatment that associate with the range...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurule, Natalia J., McCoach, Caroline E., Hinz, Trista K., Merrick, Daniel T., Van Bokhoven, Adriaan, Kim, Jihye, Patil, Tejas, Calhoun, Jacob, Nemenoff, Raphael A., Tan, Aik Choon, Doebele, Robert C., Heasley, Lynn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129124/
https://www.ncbi.nlm.nih.gov/pubmed/34001994
http://dx.doi.org/10.1038/s41698-021-00181-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129124/
https://www.ncbi.nlm.nih.gov/pubmed/34001994
http://dx.doi.org/10.1038/s41698-021-00181-4

Ejemplares similares